{
  "source": "PA-Med-Nec-Orkambi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2060-13\nProgram Prior Authorization/Medical Necessity\nMedication Orkambi™ (lumacaftor/ivacaftor)\nP&T Approval Date 5/2015, 7/2016, 11/2016, 11/2017, 9/2018, 9/2019, 10/2020, 10/2021,\n10/2022, 6/2023, 6/2024, 6/2025\nEffective Date 9/1/2025\n1. Background:\nOrkambi is a combination of lumacaftor and ivacaftor, a cystic fibrosis transmembrane\nconductance regulator (CFTR) potentiator, indicated for the treatment of cystic fibrosis (CF) in\npatients aged 1 year and older who are homozygous for the F508del mutation in the CFTR\ngene. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used\nto detect the presence of the F508del mutation on both alleles of the CFTR gene.\nLimitations of Use:\nThe efficacy and safety of Orkambi have not been established in patients with CF other than\nthose homozygous for the F508del mutation.\nMembers will be required to meet the coverage criteria below.\n2. Coverage Criteriaa:\n© 2025 UnitedHealthcare Services, Inc.\n1\nA. Initial Authorization\n1. Orkambi will be approved based upon all of the following criteria:\na. Diagnosis of cystic fibrosis (CF)\n-AND-\nb. Submission of laboratory results confirming that patient is homozygous for the F508del\nmutation in the CFTR gene.\n-AND-\nc. The patient is ≥ 1 years of age\n-AND-\nd. Prescribed by or in consultation with a provider who specializes in the treatment of CF\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Orkambi will be approved based on the following criterion:\na. Documentation of positive clinical response to Orkambi therapy (e.g., improved lung\nfunction, stable lung function)\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit plan\ncoverage may also impact coverage criteria. Other policies and utilization management programs may\napply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Cri",
    " the member specific benefit plan\ncoverage may also impact coverage criteria. Other policies and utilization management programs may\napply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Orkambi [Package Insert]. Cambridge, MA: Vertex Pharmaceuticals, Inc.; December 2024.\n© 2025 UnitedHealthcare Services, Inc.\n2\nProgram Prior Authorization/Medical Necessity – Orkambi\n(lumacaftor/ivacaftor)\nChange Control\n5/2015 New Program\n7/2015 Revised implementation date for Oxford.\n7/2016 Annual Review. Updated reference.\n11/2016 Program updated modifying age restriction as label updated for\npediatric use in patients aged 6 and older. Revised prescriber criterion.\nUpdated reference.\n11/2017 Annual Review. No changes.\n9/2018 Program updated modifying age restriction as label updated for\npediatric use in patients aged 2 and older.\n9/2019 Annual review with no changes to coverage criteria.\n10/2020 Annual review with no changes to coverage criteria. Updated reference.\n10/2021 Annual review. Reauthorization approval duration updated from 24\nmonths to 12 months.\n10/2022 Annual review. Updated background and criteria with expanded\nindication in patients aged 1 to 2 years. Updated reference.\n6/2023 Updated prescriber requirement and simplified reauthorization criteria.\nUpdated reference.\n6/2024 Annual review. Increased initial authorization approval duration to 12\nmonths. Removed prescriber requirement from reauthorization criteria.\nUpdated reference.\n6/2025 Annual review. No changes to coverage criteria. Updated reference.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}